Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Seventy percent of liver cancer patients had either a partial response or stable disease.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.